Solid Biosciences
SLDB
82 hedge funds and large institutions have $132M invested in Solid Biosciences in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 18 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
0.09% less ownership
Funds ownership: 4.65% → 4.57% (-0.09%)
10% less funds holding
Funds holding: 91 → 82 (-9)
28% less capital invested
Capital invested by funds: $184M → $132M (-$52.1M)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
73% less call options, than puts
Call options by funds: $47K | Put options by funds: $176K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.55M |
| 2 |
Millennium Management
New York
|
+$1.1M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$638K |
| 4 |
Morgan Stanley
New York
|
+$551K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$547K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.77M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$1.13M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$904K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$428K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$401K |
SLDB Hedge Fund Activity: Q4 2021 in Review
82 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q4 2021, worth a combined $132M — down 28% from $184M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of SLDB and 10 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 33 added.
The largest buyer was BlackRock, adding an estimated $3.55M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $9.77M sold.
- 82 institutional investors held Solid Biosciences (SLDB) as of Q4 2021, down from 91 in Q3 2021.
- Funds reported $132M of Solid Biosciences stock for Q4 2021, down 28% quarter-over-quarter.
- 10 funds opened new Solid Biosciences positions in Q4 2021 and 18 closed out, a net change of -8 holders.
- The largest Solid Biosciences buyer in Q4 2021 was BlackRock, an estimated $3.55M added.
- The largest Solid Biosciences seller in Q4 2021 was T. Rowe Price Associates, an estimated $9.77M sold.
Based on aggregated 13F filings for Q4 2021.